Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug;26(8):2073-89.
doi: 10.1007/s00198-015-3123-0. Epub 2015 Apr 25.

Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review

A Palermo  1 , L D'Onofrio, R Eastell, A V Schwartz, P Pozzilli, N Napoli
Affiliations
Review

Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review

A Palermo et al. Osteoporos Int. 2015 Aug.

Abstract

Fracture risk is higher in older adults with type 2 diabetes and may be influenced by treatments for diabetes. Oral anti-diabetic drugs have different effects on bone metabolism. The purpose of this review is to describe the effects of these drugs on bone metabolism and fracture risk. Osteoporosis is a progressive skeletal disorder that is characterized by compromised bone strength and increased risk of fracture. This condition has become an important global health problem, affecting approximately 200 million people worldwide. Another chronic and highly prevalent condition is diabetes mellitus, which affects more than 380 million people; both type 1 and type 2 diabetes are risk factors for fracture. Type 2 diabetes, in particular, is associated with impaired bone strength, although it is characterized by normal or elevated bone mineral density. Several therapeutic strategies are available to achieve the best outcomes in the management of diabetes mellitus but these have different effects on bone metabolism. The purpose of this narrative review is to describe the effects of oral hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones, meglitinides, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-dependent glucose transporter 2 inhibitors) on bone metabolism and on the risk of developing fragility fractures in patients with type 2 diabetes. Both diabetes and osteoporosis represent a significant burden in terms of healthcare costs and quality of life. It is very important to choose therapies for diabetes that ensure good metabolic control whilst preserving skeletal health.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Bone Miner Res. 2014 Apr;29(4):787-95 - PubMed
    1. Diabetologia. 2014 Oct;57(10):2057-65 - PubMed
    1. Eur J Endocrinol. 2011 Jan;164(1):69-74 - PubMed
    1. J Cell Physiol. 2009 Dec;221(3):740-9 - PubMed
    1. J Med Chem. 2000 Feb 24;43(4):527-50 - PubMed

MeSH terms

Substances

LinkOut - more resources